Richman D D
University of California, San Diego.
Infect Dis Clin North Am. 1988 Jun;2(2):397-407.
The first phase in the history of the chemotherapy of infection by HIV has been completed. An effective compound, AZT, has been identified that prolongs life and reduces morbidity. The next phase will be to determine the most effective and least toxic regimens of AZT and the patient populations who will most benefit. This phase will also involve the identification and evaluation of additional drugs. The most compassionate way to evaluate these drugs will be expeditious and systematic study rather than ad hoc administration and anecdotal observation. Advances in the chemotherapy of HIV infection are urgently needed. These advances will require new compounds, and because of probable drug toxicity, especially for chronic suppressive therapy, investigation must include examination of regimens that involve drug cycling and combinations.
艾滋病病毒感染化疗史上的第一阶段已经完成。一种有效的化合物齐多夫定（AZT）已被确定，它能延长生命并降低发病率。下一阶段将是确定齐多夫定最有效且毒性最小的治疗方案，以及最能从中受益的患者群体。这一阶段还将涉及鉴定和评估其他药物。评估这些药物最人道的方式将是进行迅速且系统的研究，而非临时用药和轶事观察。迫切需要在艾滋病病毒感染化疗方面取得进展。这些进展将需要新的化合物，并且由于可能存在药物毒性，特别是对于慢性抑制治疗，研究必须包括对涉及药物循环和联合用药方案的检查。
